- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01807169
Recto Colonic Endoscopic Mucosal Resection and Polypectomy Under Clopidogrel (MEDOC)
Recto Colonic Endoscopic Mucosal Resection and Polypectomy Under Clopidogrel: the "MEDOC"Study.
The endoscopic management of patients on anti platelet agents (APA) is a wide problem, with prevalence of patients on this type of therapy steadily increasing. The benefit / risk balance to stop or continue the APA for the digestive endoscopic procedure confronts us every day in clinical practice to another: the relationship thrombosis / hemorrhage.
Molecules most commonly used today are aspirin and clopidogrel. Current recommendations from the European Society of Gastrointestinal Endoscopy (ESGE) allow the maintenance of aspirin for the polypectomy. Some preliminary data show that the risk of bleeding during endoscopic mucosal resection (EMR) with aspirin is not significantly higher than polypectomy. The concept of polypectomy / EMR without stopping aspirin is progressively accepted and returned gradually to the usual practice. However, these procedures are still not allowed under clopidogrel, or in a dual APA therapy, in the absence of relevant data on the subject in the literature.
It is necessary to achieve a large national multicenter study, to clarify the risk of post recto colonic EMR and polypectomy bleeding in patients under clopidogrel alone or in combination (aspirin and clopidogrel) taking into account the endoscopic preventive measures used in daily practice by endoscopists in expert centers (clip, ligature and loop devices, preventive adrenalin injection).
The aim of the "MEDOC" study is to determine the incidence of immediate and delayed bleeding after colonic polypectomy and / or EMR for patients on clopidogrel.
It is expected in this work an incidence of post-polypectomy bleeding close to that observed during the implementation of these actions in the population without any anti platelet agents.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The endoscopic management of patients on anti platelet agents (APA) is a wide problem, due to the dramatically increasing prevalence of patients on these therapies. The benefit / risk balance to stop or continue the APA for the digestive endoscopic procedure confronts us every day in clinical practice to another: the relationship thrombosis / hemorrhage. The maintenance of an APA is particularly essential for acute coronary episode, but in the long term, in prevention of recurrent thrombotic cardiovascular disease. Molecules most commonly used today are aspirin and clopidogrel.
Current recommendations from the European Society of Gastrointestinal Endoscopy (ESGE) allow the maintenance of aspirin for the polypectomy. Some preliminary data show that the risk of bleeding during endoscopic mucosal resection (EMR) with aspirin is not significantly higher than polypectomy. The concept of polypectomy / EMR without stopping aspirin is progressively accepted and returned gradually to the usual practice. However, these procedures are still not allowed under clopidogrel, or in a dual APA therapy, in the absence of relevant data on the subject in the literature.
However recent studies disrupt this problem for different reasons: i) endoscopic haemostatic preventive measures have demonstrated efficacy in reducing the rate of immediate and delayed bleeding post polypectomy or EMR; ii) the inadequate modification or untimely stopping APA treatment is always complicated by severe vascular thrombosis events in 5% of patients; iii) three retrospective studies relativize the risk of bleeding after a colonic polypectomy under clopidogrel. It is therefore essential to carry out a prospective, large-scale, multicenter, study to clarify the risk of post colonic EMR/polypectomy bleeding in patients under clopidogrel alone or in combination (aspirin and clopidogrel) taking into account the endoscopic preventive measures used in daily practice by endoscopists in expert centers (clip, ligature and loop devices, preventive adrenalin injection).
The aim of the "MEDOC" study is to determine the incidence of immediate and delayed bleeding after colonic polypectomy and / or EMR for patients on clopidogrel.
The study presents an interventional prospective multicentric and national design.
300 patients will be included. The duration of the study inclusions will be 18 months.
It is expected in this work an incidence of post-polypectomy bleeding close to that observed during the implementation of these actions in the population without any anti platelet agents.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33400
- Centre hospitalier Universitaire de Bordeaux
-
Brest, France, 29609
- Centre Hospitalier Universitaire de Brest
-
Nice, France, 06003
- Centre Hospitalier Universitaire de Nice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years, male or female
- Polypectomy AND / OR mucosectomy (EMR) performed on clopidogrel and/or aspirin during a colonoscopy with inability to defer action
- Taking a single daily dose of clopidogrel long-term (more than 3 months) or under treatment with clopidogrel and aspirin (aspirin < 375 mg more than 3 months) in the prevention of cardiovascular and thromboembolic risk with a major or medium - secondary prevention
- Affiliation to the regime of national health protection
- Informed consent and patient's written obtained
- No participation in another clinical study
Exclusion Criteria:
- Contraindications to the achievement of a lower gastrointestinal endoscopy
- Taking a single daily dose of clopidogrel or other anti-platelet, anti vitamin K (AVK), heparin or anti bi aggregation in the context of cardiovascular prevention
- Taking chronic anti inflammatory drug (at least once weekly)
- Resection technique submucosal dissection
- Haemorrhagic disease, disorders of hemostasis and coagulation (PT <60%, aPTT> 40 sec. And platelets <100000/mm3), hematologic malignancy, chronic liver cirrhosis classified as Child Pugh B or C, acute or chronic renal failure
- Acute Coronary Syndrome <3 months or not received percutaneous coronary intervention (PCI).
- Angioplasty with placement of a stent drug evaluation (out of context of acute coronary syndrome) <3 months.
- Angioplasty with placement of a bare metal stent (out of context of acute coronary syndrome) <4 weeks.
- Pregnant women, nursing
- Not signing the written consent and / or mental disabilities of the subject making its participation in the trial impossible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Colonic polypectomy or endoscopic mucosal resection
Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
|
Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of delayed bleeding after polypectomy and / or colonic mucosectomy
Time Frame: during surgery, hospitalization and at 30 days
|
Incidence of delayed bleeding after polypectomy and / or colonic mucosectomy (endoscopic mucosal resection) in patients on clopidogrel
|
during surgery, hospitalization and at 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of immediate bleeding after polypectomy and / or colonic mucosectomy
Time Frame: during surgery, hospitalization and at 30 days
|
during surgery, hospitalization and at 30 days
|
|
Incidence of severe bleeding after polypectomy and / or colonic mucosectomy in patients on Clopidogrel
Time Frame: during surgery, hospitalization and at 30 days
|
during surgery, hospitalization and at 30 days
|
|
Efficacy of endoscopic hemostasis in case of bleeding induced
Time Frame: in case of bleeding induced
|
Defined by the cessation of bleeding without the need for further treatment (surgery, radiation)
|
in case of bleeding induced
|
morbidity / mortality induced by immediate and delayed bleeding after polypectomy and / or colonic mucosectomy in patients on clopidogrel
Time Frame: during surgery, hospitalization and at 30 days
|
during surgery, hospitalization and at 30 days
|
|
predictors of gastrointestinal bleeding post polypectomy / mucosectomy under clopidogrel by sub groups of patients obtained
Time Frame: during surgery, hospitalization and at 30 days
|
during surgery, hospitalization and at 30 days
|
Collaborators and Investigators
Investigators
- Study Director: Geoffroy VANBIERVLIET, MD, Centre Hospitalier Universitaire de Nice
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 12-AOI-05
- 2012-005365-12 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polyps
-
Eisai Inc.PPD; Covance; Quest Pharmaceutical ServicesTerminated
-
Eisai Inc.Omnicare Clinical Research; MDS Pharma Services; Bio Analytical Research Corporation and other collaboratorsCompletedColonoscopy | Colon Polyps
-
Eisai Inc.PPD; MDS Pharma Services; Bio Analytical Research Corporation; Coghlan Group (Plasma...CompletedColonoscopy | Colon Polyps
-
Affiliated Hospital to Academy of Military Medical...UnknownSmall Colon Polyps | Linked Color Imagimg | Diminutive Colon PolypsChina
-
Biotax Labs LTDRecruiting
-
Seoul National University HospitalCompletedColon PolypKorea, Republic of
-
Portuguese Oncology Institute, CoimbraCompleted
-
VA Greater Los Angeles Healthcare SystemTerminatedScreening of Colonic PolypsUnited States
-
M.D. Anderson Cancer CenterRecruitingColon PolypsUnited States
-
White River Junction Veterans Affairs Medical CenterDartmouth College; Boston Scientific CorporationActive, not recruitingColon PolypsUnited States
Clinical Trials on Colonic polypectomy or endoscopic mucosal resection (EMR).
-
Universitätsklinikum Hamburg-EppendorfTerminatedColorectal Adenomatous Polyp | Colorectal Adenoma With Mild Dysplasia | Colorectal Adenoma With Severe Dysplasia | Colorectal Low Grade Intraepithelial Neoplasia | Colorectal High Grade Intraepithelial NeoplasiaGermany, United Kingdom
-
Instituto do Cancer do Estado de São PauloUniversity of Sao PauloCompletedColorectal Neoplasms | AdenomaBrazil
-
Société Française d'Endoscopie DigestiveCompleted
-
Massachusetts General HospitalUnknownChronic Constipation | Hirschsprung's DiseaseUnited States
-
Massachusetts General HospitalCompletedConstipation | Hirschsprung DiseaseUnited States
-
Unity Health TorontoNot yet recruiting10-20mm Colorectal Polyp
-
University of British ColumbiaRecruitingColon Adenoma | Colon Polyp | Colon LesionCanada
-
Western Sydney Local Health DistrictCompletedColorectal Cancer | AdenomaAustralia
-
UMC UtrechtComprehensive Cancer Centre The NetherlandsUnknownColorectal NeoplasmsNetherlands
-
Ningbo No. 1 HospitalRecruitingHaemorrhage | Pedunculated Colorectal PolypsChina